[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369998-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369998-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multicancer-early-detection-blood-test-performance-in-cancer-survivors-from-the-pathfinder-study","Multicancer Early Detection Blood Test Performance in Cancer Survivors From the PATHFINDER Study","","Cancer survivors face elevated risks of recurrence and second primary cancers, yet long-term surveillance guidance is often unclear. Performance of a blood-based multicancer early detection (MCED) test was evaluated in 1,609 PATHFINDER participants, a prospective cohort without current suspicion of cancer. A cancer signal was detected in 1.2% (20/1,609), leading to ten new diagnoses (recurrences and second primaries) with similar test metrics across prior cancer histories.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multicancer-early-detection-blood-test-performance-in-cancer-survivors-from-the-pathfinder-study/369998/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multicancer-early-detection-blood-test-performance-in-cancer-survivors-from-the-pathfinder-study/369998.png","ImageObject",300,407,{"name":42,"@type":43},"nayy☆","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about cancer survivor surveillance?","Question",{"text":63,"@type":64},"It evaluates whether blood-based multicancer early detection (MCED) testing adds value for detecting recurrence and second primary cancers in cancer survivors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the MCED test evaluated in the PATHFINDER study?",{"text":68,"@type":64},"The test performance was assessed in 1,609 survivors participating in PATHFINDER, a prospective study of adults without current suspicion of cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main results regarding detection and new diagnoses?",{"text":72,"@type":64},"A cancer signal was detected in 1.2% (20/1,609). Ten new cancer diagnoses occurred, including both recurrences and second primaries, with similar performance in participants with and without prior cancer history.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369998,1790236296,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Original Reports | Diagnostics  \nMulticancer Early Detection Blood Test Performance in Cancer Survivors From the PATHFINDER Study  \nCatherine R. Marinac, PhD1  ; Elizabeth K. O’Donnell, MD1; Christina A. Clarke, PhD, MPH2; Margarita Lopatin, MS2; Eric T. Fung, MD, PhD2  ; and Eric A. Klein, MD2   \nDOI [https://doi.org/10.1200/PO-25-00498](https://doi.org/10.1200/PO-25-00498)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Cancer survivors are at risk for recurrence and second primaries, yet often lack clear guidance for long-term surveillance. |\n| METHODS | We assessed the performance of a blood-based multicancer early detection (MCED) test in 1,609 survivors who participated in PATHFINDER, a prospective study of adults without current suspicion of cancer. |\n| RESULTS | Previous cancers included breast (47%), melanoma (10%), prostate (9%), colorectal (4%), and lymphoma (4%) . Average time since diagnosis was 11.2 years, and a cancer signal was detected in 1.2%(20/1,609) . Ten new cancer diagnoses occurred: 5 second primaries (stage I uterine, stage II sarcoma, stage III ovarian, stage IV lymphoma, and stage IV colorectal) 8-15 years after original diagnosis and ﬁve recurrences (breast cancer) 4-11 years after original diagnosis. Test performance metrics were similar in those with and without previous cancer history. |\n| CONCLUSION | These ﬁndings highlight the potential of MCED tests to address a signiﬁcantunmet need in long-term surveillance of survivors. |\n\nACCOMPANYING CONTENT  \n Appendix  \nAccepted November 4, 2025 Published December 18, 2025  \nJCO Precis Oncol 9:e2500498 © 2025 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nWith ongoing advances in diagnostic technology and treatment efﬁcacy, the number of cancer survivors continues to grow worldwide. As of January 2022, there were 18.1 million cancer survivors in the United States, with a projected increase to 26 million by 2040.1 Long-term survival among patients with cancer is increasingly common; in 2022, 70% of cancer survivors had lived ≥5 years after diagnosis and 11% survived for 25 years or more.1 By 2040, a 53% increase to 19.2 million individuals living ≥5 years from their original diagnosis is expected.1  \nSurvivors face an increased risk of either cancer recurrence or the development of a new, second primary cancer after their initial diagnosis. The risk of these events varies by cancer type and treatment response, and clear guidance for monitoring survivors is often lacking. For example, in areview of 41 disease-monitoring guidelines published between 2010 and 2016, ambiguous recommendations, deﬁned as either omitting a modality or discussing it without providing a clear directive, were noted in 83% .2 Furthermore, primary care providers are increasingly responsible for caring for this growing population and may lack familiarity with recommended surveillance strategies,2 an  \nissue identiﬁed in a National Academies Report in 2006 that has not yet been satisfactorily addressed.3 Given the current prevalence and the anticipated rise in long-term cancer survival, there is a pressing need for enhanced monitoring of this population.  \nBlood-based multicancer early detection (MCED) tests that detect a cancer signal shared across multiple cancer types hold promise for addressing this need. Case-control and prospective studies have shown that MCED tests can detect a wide range of malignancies.4-6 One such study, PATHFINDER ([ClinicalTrials.gov](ClinicalTrials.gov) identiﬁer: NCT04241796), was a prospective study investigating the feasibility of a targeted methylation-based MCED test for cancer screening in individuals age 50 years and older without signs or symptoms associated with suspicion of cancer.7 The test detected both recurrent and nonrecurrent cancers, with almost half (48%) of the nonrecurrent cancers detected at early stage (stage I or II) . Participants in PATHFINDER include","cbCain8uTzUtWFTm","https://ap.wps.com/l/cbCain8uTzUtWFTm","pdf",2005069,13,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance\n# Methods\n## MCED Test","[{\"question\":\"What question does the study address about cancer survivor surveillance?\",\"answer\":\"It evaluates whether blood-based multicancer early detection (MCED) testing adds value for detecting recurrence and second primary cancers in cancer survivors.\"},{\"question\":\"How was the MCED test evaluated in the PATHFINDER study?\",\"answer\":\"The test performance was assessed in 1,609 survivors participating in PATHFINDER, a prospective study of adults without current suspicion of cancer.\"},{\"question\":\"What were the main results regarding detection and new diagnoses?\",\"answer\":\"A cancer signal was detected in 1.2% (20/1,609). Ten new cancer diagnoses occurred, including both recurrences and second primaries, with similar performance in participants with and without prior cancer history.\"}]","Multicancer Early Detection Blood Test Performance in Cancer Survivors From the PATHFINDER Study | PDF",1790186199,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cfc004df46869428a7f6d3ff03abbca.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f6f7210dd04cfccbc07c76029da499e.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cdaec04b5329a4592896b7575b6cb26a.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc6ddaadbd8dad5ac77c5899582d803a.webp",980,1311]